Baxter International, Inc. operates as a healthcare company worldwide. It offers medical devices, pharmaceuticals, and biotechnology products for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. The BioScience segment manufactures recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as proteins used in hemostasis, wound-sealing, and tissue regeneration; and vaccines. The Medication Delivery segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to drug formulation and packaging technologies. The Renal segment provides products to treat end-stage renal disease, or irreversible kidney failure. It also manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy; and distributes products for hemodialysis (HD), which is conducted in a hospital or clinic. It markets its products through independent distributors, drug wholesalers, specialty pharmacy, and homecare companies to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. The company has a collaboration agreement with HHD, LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. to develop a home HD machine. Baxter International was founded in 1931 and is based in Deerfield, Illinois.